Open account
Sign up/Log in
Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why
Eisai and Biogen's Leqembi is the first drug shown to slow Alzheimer’s progression. The drug faces skepticism among some doctors. Interviews with 20 neurologists and geriatricians revealed concerns about efficacy, costs, and risks of the drug.
Benzinga · 16h ago
European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab
Biogen Inc and Eisai Co Ltd faced a setback as the oral explanation of lecanemab was postponed. The delay has implications for the review process of a pivotal drug currently under evaluation by the European Medicines Agency. The Oral Explanation was slated for March 19.
Benzinga · 03/22 17:44
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
The FDA is expected to delay its decision on Eli Lilly's Alzheimer's drug. The drug, donanemab, would compete with Biogen’s Leqembi. The FDA will convene an advisory committee to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial.
Benzinga · 03/08 13:58
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says
Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, down 6% Y/Y. Biogen's partner, Eisai Co Ltd, has faced a delay in reaching the 10,000-patient mark for Leqembi. Baird analyst has lowered the price target to $316 from $333.
Benzinga · 02/14 20:11
Why Is Biogen Stock Trading Lower On Tuesday?
Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, down 6% Y/Y and 5% at constant currency. European Commission approved Skyclarys for Friedreich's ataxia on Tuesday.
Benzinga · 02/13 17:42
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
Washington University School of Medicine pioneered blood tests capable of detecting sticky amyloid plaques, a key Alzheimer's indicator. Current blood tests for Alzheimer’s lack sufficient regulation, and none have received FDA approval. Blood tests offer a quick and less invasive way to identify patients and determine eligibility for emerging drugs.
Benzinga · 01/12 18:17
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
Leap-001 trial of keytruda and lenvima did not meet primary endpoints. Merck & co and eisai failed to meet endpoints of overall survival and progression-free survival for patients with endometrial carcinoma. The trial included patients with advanced or recurrent endometriosis.
Benzinga · 12/08/2023 13:26
Alzheimer's Disease Drug Development: Another Lost Year
Investing in most current alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of alzheimer's disease over the short term. The fda's approval of anti-amyloid drug leqembi was a failure.
Seeking Alpha · 12/05/2023 08:58
Webull offers Eisai stock information, including OTCPK: ESALY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESALY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading ESALY stock methods without spending real money on the virtual paper trading platform.